Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Enfortumab Vedotin Achieves Responses in Advanced Urothelial Carcinoma
June 3rd 2019According to data from the phase II EV-201 study presented at the 2019 ASCO Annual Meeting, 44% of patients with locally advanced or metastatic urothelial cancer achieved responses with enfortumab vedotin. This includes 12% of patients reached a complete response to treatment. Median overall survival time for patients was 11.7 months.
PFS Increased With Olaparib as Maintenance Therapy for BRCA+ Metastatic Pancreatic Cancer
June 2nd 2019The PARP inhibitor olaparib significantly improved progression-free survival in patients with germline BRCA-mutated metastatic pancreatic cancer compared to placebo when used as maintenance therapy in the phase III POLO trial, presented at the 2019 ASCO Annual Meeting.
Less AEs, Similar Efficacy Reported in Advanced G/GEJ Cancers With Frontline Pembrolizumab
June 1st 2019Patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer had non-inferior overall survival with frontline pembrolizumab compared with standard chemotherapy, according to results from the phase III KEYNOTE-062 trial.
Risk of Progression Reduced With Lenalidomide in Smoldering Multiple Myeloma
May 16th 2019Lenalidomide induced a 72% reduction in the risk of progression to symptomatic disease in patients with smoldering multiple myeloma at 3 years, according to data from the ECOG E3A06 study, to be presented during the 2019 ASCO Annual Meeting.
Durable Responses Seen With Dostarlimab in MSI-H, MSS Endometrial Tumors
March 25th 2019According to results from the ongoing phase I/II GARNET trial, dostarlimab induced an overall response rate of nearly 30% in patients with recurrent or advanced endometrial cancer. Results presented at the 2019 SGO Annual Meeting also demonstrated durable responses in both patients with microsatellite instability-high and microsatellite stable tumors.
Olaparib Combined With Neratinib May Be Novel Option for HER2+ Ovarian Cancer
March 20th 2019Olaparib combined with neratinib may be a novel treatment option for patients with HER2-positive, homologous recombination–proficient ovarian cancer tumors that are resistant to chemotherapy, preclinical findings presented during the 2019 SGO Annual Meeting showed.<br />
Promising Findings Seen With Neratinib in HER2-Mutant Cervical Cancer
March 19th 2019Neratinib demonstrated durable responses and disease control and a manageable safety profile in patients with metastatic <em>HER2</em>-mutant cervical cancer, according to results from the ongoing phase II SUMMIT basket trial.
Durable Responses Seen With Pembrolizumab/Bevacizumab Regimen in Ovarian Cancer
March 18th 2019Women with recurrent ovarian cancer treated with the combination of pembrolizumab, bevacizumab, and metronomic cyclophosphamide had a 95% disease control rate and a 40% overall response rate, according to findings from an open-label phase II study presented during the 2019 SGO Annual Meeting.
Lenvatinib Plus Paclitaxel Shows Activity in Ovarian, Endometrial Cancers
March 18th 2019Activity was seen with lenvatinib plus a weekly dose of paclitaxel in patients with recurrent endometrial and platinum-resistant epitherlial ovarian cancer, according to a presentation at the 50th SGO Annual Meeting. The combination resulted in a 65% overall response rate in a phase I trial.
TEAEs Decreased With Individualized Dose of Niraparib in High-Risk Ovarian Cancer
March 17th 2019Patients with high-risk ovarian cancer being treated with niraparib experienced a decrease in adverse events when treated with a 200- or 300-mg individualized starting dose based on bodyweight and platelet count compared with patients who received a fixed starting dose of 300 mg, according to data from a recent analysis of the ongoing ENGOT-OV26/PRIMA study.
Repeat PARP Use May Benefit Women With Recurrent Ovarian Cancer
March 17th 2019Repeated use of PARP inhibitors may be a beneficial treatment strategy in the future for women with recurrent epithelial ovarian cancer, according to the results of a retrospective, multi-institutional study presented at the 2019 SGO Annual Meeting. The findings suggested that prior exposure to PARP inhibition may not lead to resistance, which could lead to increased use of repeat PARP treatment going forward.
PFS Increased With Niraparib Without Symptoms or Toxicity in Ovarian Cancer
March 17th 2019Treatment with maintenance niraparib led to extended progression-free survival time in patients with recurrent ovarian cancer without the patients experiencing symptoms or toxicity compared with placebo, according to results of an analysis from the phase III ENGOT-OV16/NOVA trial. In patients with germline <em>BRCA</em>-mutated disease, the benefit was increased 4-fold and in patients non–germline <em>BRCA</em>-mutated ovarian cancer the benefit was increased 2-fold.
Study Confirms Utility of Liquid Biopsies for Biomarker Detection in NSCLC
February 28th 2019Guardant360—a 73-gene next-generation sequencing panel—detected all of the guideline-recommended biomarkers in patients newly diagnosed with metastatic non–small cell lung cancer at a similar rate, but in a faster turnaround time than tissue genotyping, according to data from the NILE study.
Hormonal Agents Lead to Improved Outcomes in African Americans With Chemo-Naive mCRPC
February 12th 2019Although African-American men are at a higher risk for metastatic castration-resistant prostate cancer and have worse survival outcomes compared with Caucasian men, findings of a recent retrospective study suggested they may have a better response to several prostate cancer treatments.
Potential Seen With Rivaroxaban for Reducing Blood Clot Risk During Systemic Therapy
December 6th 2018According to data from the phase IIIb CASSINI trial presented at the 2018 ASH Annual Meeting, rivaroxaban could significantly reduce venous thromboembolism occurrence in patients currently receiving treatment with systemic therapy.
Achieving pCR After Neoadjuvant Chemo Linked to Improved Outcomes in Breast Cancer
December 6th 2018Patients with breast cancer who achieved pathologic complete response following neoadjuvant chemotherapy were more likely to have improved survival outcomes, according to findings of a meta-analyses data presented at the 2018 San Antonio Breast Cancer Symposium.
New Personalized Approach Improves Survival Prediction in Patients With MDS
December 3rd 2018The gold standard of predicting how long patients with myelodysplastic syndromes could live with the disease may soon be replaced by a new approach. According to Aziz Nazha, MD, this newer approach utilizes machine learning to analyze genomic and clinical data from patients to more accurately predict survival.
Rapid AML Subtype Assessment Possible at Diagnosis, Collaborative Trial Shows
December 3rd 2018It may be possible for hematologists to determine subtypes of acute myeloid leukemia based on genetic analsysis of blood samples in 7 days or less. According to Amy Burd, PhD, this process could play an important role in diagnosing and treating patients.
Risk of Relapse Reduced With HCT Following CAR T-Cell Therapy in ALL
December 2nd 2018Patients with acute lymphoblastic leukemia saw a reduction in the risk for recurrence after receiving a stem cell transplant for the first time following treatment with CD19 chimeric antigen receptor T-cell therapy.
Update Supports Durvalumab With Chemoradiotherapy as Standard for Unresectable Stage III NSCLC
October 9th 2018Durvalumab (Imfinzi) demonstrated an improvement in overall survival compared with placebo in patients with stage III, unresectable non–small cell lung cancer who have not progressed following chemoradiotherapy, according to updated findings from the PACIFIC trial recently presented at the 19th World Conference on Lung Cancer and simultaneously published in the <em>New England Journal of Medicine</em>.
Lurbinectedin Combo Active in Chemo-Sensitive SCLC
October 1st 2018Second-line treatment with the combination of lurbinectedin (Zepsyre; PM1183) and doxorubicin demonstrated significant clinical activity in patients with small cell lung cancer, especially when excluding refractory patients, according to findings presented at the 19th World Conference on Lung Cancer in Toronto, Canada.
Subgroup of NSCLC Patients May Benefit From Entinostat/Pembrolizumab Combo
September 27th 2018Enhanced clinical benefit may be derived from the combination of entinostat and pembrolizumab (Keytruda) in a subgroup of patients with PD-1/PD-L1–refractory non–small cell lung cancer who have high levels of peripheral blood monocytes, ongoing analyses suggest.
Atezolizumab Demonstrates OS Improvement in SCLC
September 26th 2018Adding atezolizumab (Tecentriq) to standard carboplatin and etoposide significantly prolonged survival in patients with extensive-stage small cell lung cancer compared with the chemotherapy regimen alone in the frontline setting, according to results from the IMpower133 study.
Brigatinib Superior to Standard of Care Crizotinib in ALK+ NSCLC
September 26th 2018Adult patients with <em>ALK</em>-positive, locally advanced or metastatic non–small cell lung cancer who had not received a prior ALK inhibitor experienced a more than 50% reduction in the risk of disease progression or death with treatment with brigatinib (Alunbrig), compared with the first-line standard of care, crizotinib.
Repotrectinib Demonstrates Promising Benefit in Patients With ROS1+ NSCLC
September 26th 2018Patients with <em>ROS1</em> fusion–positive non–small cell lung cancer had clinically meaningful and durable benefit across multiple doses of repotrectinib (TPX-0005), according to interim findings from the ongoing phase I/II TRIDENT-1 study, presented at the 19th World Conference on Lung Cancer.
Promising Efficacy Seen With Poziotinib in Heavily Pretreated EGFR/HER2+ NSCLC
September 26th 2018Promising efficacy was seen with the novel targeted therapy poziotinib in patients with metastatic, heavily pretreated <em>EGFR </em>and <em>HER2 </em>exon 20 mutant non–small cell lung cancer, with a best response rate to date of 55%, according to phase II study results presented at the 19th World Conference on Lung Cancer.
Frontline Pembrolizumab Granted Priority Review by FDA for Lower PD-L1 Cutoff in NSCLC
September 12th 2018A supplemental biologics license application for pembrolizumab (Keytruda) has been granted a priority review designation by the FDA for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no <em>EGFR</em> or <em>ALK</em> genomic tumor aberrations.
No Benefit From Added Heated Chemotherapy in Advanced Colorectal Cancer
June 5th 2018In patients with peritoneal carcinomatosis undergoing surgery, the addition of heated chemotherapy to the abdomen during surgery did not provide a survival benefit, data from a phase III study presented at the 2018 ASCO Annual Meeting, in Chicago, Illinois, showed.
KEYNOTE-042 Data Suggest Survival Improvement With Pembrolizumab in NSCLC
June 3rd 2018According to findings from the phase III KEYNOTE-042 trial, patients with non–small cell lung cancer demonstrated improved survival of 4 to 8 extra months with upfront pembrolizumab therapy compared with chemotherapy, the current standard of care. Patients treated with pembrolizumab also experienced fewer adverse events.